The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit.
Read More
Children and adults respond differently to medications for ADHD. This first-of-its-kind trial tested out the pediatric-approved guanfacine ER (Intuniv) in adult ADHD.
Read More
There are many mood stabilizers to choose from, but which ones are the best tolerated? This meta-analysis looks at how they stack up in terms of weight gain, sedation, and overall discontinuation.
Read More
Ruta Nonacs names the antidepressants that work best for menopausal depression and when to move to hormonal therapies. And for adolescents and young adults, she tells us which birth control pills are least likely to worsen mood.
Read More
Not satisfied with its claim to improve cognitive features of depression, Trintellix has ventured into new therapeutic arenas. Sometimes with success, sometimes with failure, we review where this novel antidepressant stands in schizophrenia, anxiety, cognitive decline, ADHD, sexual dysfunction, and binge eating disorder.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
